Associated Papers
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC.
Wang Q et al.
Frontiers in Oncology, 2023
37441425 (PubMed )
Supplement: Table_3.xlsx › mutations
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
36068297 (PubMed )
Supplement: 41397_2022_288_MOESM4_ESM.xlsx › Sheet1
Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes.
El-Boraie A et al.
Clinical and Translational Science, 2022
Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
Zahra MA et al.
Biomed Research International, 2020
Accurate diagnosis of mismatch repair deficiency in colorectal cancer using high-quality DNA samples from cultured stem cells.
Yamaura T et al.
Oncotarget, 2018
30680068 (PubMed )
Supplement: oncotarget-09-37534-s002.xlsx › MSI-H
NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis.
Jiménez-Jiménez FJ et al.
Expert Opinion on Drug Metabolism & Toxicology, 2016
Genetic variability in N-acetyltransferase 2 gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil.
Zanrosso CW et al.
Leukemia & Lymphoma, 2012
Genetic basis of toxic reactions to drugs and chemicals.
Cascorbi I
Toxicology Letters, 2006
[Restriction analysis of N-acetyltransferase 2 gene in Caucasian population of West Siberia].
Nikishina MV et al.
Genetika, 2004
Analysis of six SNPs of NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the Embera acetylation phenotype using caffeine.
Jorge-Nebert LF et al.
Pharmacogenetics, 2002
N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review.
Brockton N et al.
American Journal of Epidemiology, 2000
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
McElroy S et al.
Aaps Pharmsci, 2000
Select a paper to view details